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Background: In humans mutations in the PLN gene, encoding phospholamban - a regulator of sarcoplasmic reticulum
calcium ATPase (SERCA), cause cardiomyopathy with prevalence depending on the population. Our purpose was to
identify PLN mutations in Polish cardiomyopathy patients.
Methods: We studied 161 unrelated subjects referred for genetic testing for cardiomyopathies: 135 with dilated
cardiomyopathy, 22 with hypertrophic cardiomyopathy and 4 with other cardiomyopathies. In 23 subjects multiple
genes were sequenced by next generation sequencing and in all subjects PLN exons were analyzed by Sanger
sequencing. Control group included 200 healthy subjects matched with patients for ethnicity, sex and age. Large
deletions/insertions were screened by real time polymerase chain reaction.
Results: We detected three different heterozygous mutations in the PLN gene: a novel null c.9_10insA:(p.Val4Serfs*15)
variant and two missense variants: c.25C > T:(p.Arg9Cys) and c.26G > T:(p.Arg9Leu). The (p.Val4Serfs*15) variant
occurred in the patient with Wolff-Parkinson-White syndrome in whom the diagnosis of cardiomyopathy was not
confirmed and his mother who had concentric left ventricular remodeling but normal left ventricular mass and
function. We did not detect large deletions/insertions in PLN in cohort studied.
Conclusions: In Poland, similar to most populations, PLN mutations rarely cause cardiomyopathy. The 9th PLN
residue is apparently a mutation hot spot whereas a single dose of c.9_10insA, and likely other null PLN mutations,
cause the disease only with low penetrance or are not pathogenic.
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To date over 50 genes have been linked to cardiomyopa-
thies, including PLN - a reversible inhibitor of cardiac
sarcoplasmic reticulum calcium ATPase isoform 2a (SER-
CA2a). SERCA is responsible for around 70% of Ca2+
reuptake from cytosol into sarcoplasmatic reticulum and
is a key regulator of cardiac muscle contractility [1]. PLN
is a small 52 amino acid protein consisting of cytosolic do-
main IA (amino acids 1–20), unstructured domain IB (aa
21–30) and domain II which forms transmembrane helix.
PLN is embedded in sarcoplasmic reticulum (SR) mem-
brane close to the SERCA protein. PLN regulation of SER-
CA2a activity depends on PLN phosphorylation and
cytosolic Ca2+ concentrations. PLN can be phosphorytaled
at Serine 16 by the cAMP-dependent protein kinase
(PKA) and at Thyrosine 17 by Ca2+ - calmodulin-
dependent protein kinase (CAMKII) [2] or serine/threo-
nine kinase Akt, also referred to as protein kinase B [3]. In
the dephosphorylated state PLN binds to SERCA2a de-
creasing its affinity for Ca2+. The monomer form of PLN
inhibits SERCA2a calcium re-uptake from cytosol into the
SR [4] whereas phosphorylation by PKA enhances the for-
mation of PLN pentamers and relieves the inhibition of
SERCA2a. Mutations in PLN have been found in dilated
cardiomyopathy (DCM), arrhythmogenic right ventricular
cardiomyopathy (ARVC) and hypertrophic cardiomyop-
athy (HCM) patients [5-7]. So far only one c.T116G:(p.
Leu39Ter) truncating PLN mutation has been described
[8]. The prevalence of PLN mutations in DCM patients is
generally below 1.5%, but in Dutch population the
c.40_42delAGA:(p.Arg14del) mutation was found in 12%
of DCM and 15% of ARVC patients [5,6]. As this has not
been studied before, the aim of our project was to deter-




The study cohort was drawn from all index patients re-
ferred for clinical and genetic testing for cardiomyopa-
thies from 1st January, 2010 to 31st March 2014 to the
Unit for Screening Studies in Inherited Cardiovascular
Diseases. It consisted of 161 unrelated probands (30.4%
females, mean age 40.9 year, standard deviation 12.9),
135 with DCM, including 20 heart transplant recipients,
22 with HCM and 4 with a diagnosis of other cardiomyop-
athies (three with left ventricular non-compaction (LVNC)
and one with restrictive cardiomyopathy (RCM)). The
diagnosis was based on ESC criteria [9] after a careful
examination of medical records and clinical work-up
including standard 12-lead electrocardiogram (ECG)
and two-dimensional Doppler echocardiography in all
probands except for heart transplant recipients, whose
medical records were reviewed retrospectively. Furtherdiagnostic tests - 24-hour Holter ECG monitoring, exer-
cise stress test were performed if necessary. Creatine
phosphokinase (CPK) concentration was obtained when-
ever possible. All DCM probands underwent either coron-
ary angiography or, more recently, coronary computed
tomography angiography (CTA). Cardiac magnetic reson-
ance (CMR) imaging was performed in selected patients
at the discretion of the referring physician. Cardiomyop-
athy was considered familial when two subjects in a family
met the diagnostic criteria for the same cardiomyopathy
as proband’s.
Controls
Age and sex matched control group (N = 200, 30% fe-
males, mean age 40.5 years with SD 13.0) was selected
from WOBASZ II study, which is a cross-sectional
population-based study aimed at delineation of classical
and genetic risk factors for cardiovascular diseases. The
WOBASZ II participants were randomly chosen from
the Polish population register of permanent residents
aged 20–74 years from the whole territory of Poland
[10]. Each patient and their relative(s) gave their written
informed consent to participate in the study in accord-
ance with the Declaration of Helsinki and the study
protocol was approved by the local bioethics committee
(Ethics Committee of the Cardinal Wyszynski Institute
of Cardiology).
Genetic testing
DNA was extracted from the peripheral blood by phenol
extraction. Multiple gene screening was initially per-
formed by next-generation sequencing (NGS) in 23 pa-
tients (in 15 patients whole exome sequencing (WES)
was performed; the remaining eight subjects were tested
by targeted sequencing of a panel of 35 genes involved
in cardiomyopathies, Additional file 1). WES was per-
formed on HiSeq 1500 using TruSeq Exome Enrichment
Kit (Illumina) as described previously [11]. Targeted
sequencing of 35 genes was performed using a custom
design SeqCap EZ Choice Library (Roche NimbleGen)
of ~0,34 Mb target genomic sequences. The whole pro-
cedure was carried out according to SeqCap EZ Library
SR User’s Guide v.3.0, with modifications, briefly de-
scribed below. 1 μg of genomic DNA was fragmented by
a 2 min sonication using Covaris M220. Genomic librar-
ies were prepared using TruSeq Library Preparation Kit
(Illumina), according to the low-throughput protocol (revi-
sion C, June 2011) with gel-free size selection method
employing Agencourt AMPure XP (Beckman Coulter)
magnetic beads. Sample libraries were pooled (12-plex) to
a total of 1 μg and hybridized with SeqCap EZ probes for 3
days at 47°C. Captured sequences were purified with Dyna-
beads M-270 Streptavidin (Invitrogen), amplified, cleaned
up and proceeded to sequencing. During the procedure,
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using Kapa HotStart ReadyMix (Kapa Biosystems) instead
of the recommended PCR master mix and cleaned up
using AMPure XP beads. Libraries were quantified fluoro-
metrically using Qubit 2.0 (Life Technologies) and quality
assessment was done on 2100 Bioanalyser (Agilent Tech-
nologies). The libraries were sequenced on HiSeq 1500
(Illumina).
Prompted by finding of a mutation in the PLN gene
c.26G>T:(p.Arg9Leu) in one patient studied by WES we
performed single-gene testing of PLN by Sanger sequen-
cing in additional 138 cardiomyopathy patients as well
as the 23 subjects initially studied by NGS (161 subjects
in total). Primers were designed to include the promoter
region (up to −316 bp upstream of the transcript start
site) with the first (non-coding) exon, the second (pro-
tein coding) exon and the splice sites (Additional file 2).
In the control group Sanger sequencing was limited to
PLN exon 2 (the only protein coding PLN exon). The PCR
conditions were: 5 min of initial denaturation at 95°C,
followed by 32 cycles of 30 sec at 95°C, 55 sec at 62°C,
1 min at 72°C and final extension of 10 min at 72°C.
PCR products were examined on 2 % agarose gels,
cleaned-up with exonuclease I and alkaline phosphatase
(Thermo Scientific) and sequenced using a 3500xL Gen-
etic Analyzer (Applied Biosystems) and BigDye Termin-
ator v3.1 Cycle Sequencing Kit (Applied Biosystems)
according to the manufacturer’s instructions. The results
were analyzed with Variant Reporter 1.1 Software (Applied
Biosystems).
Among the patients we also performed an analysis of
copy number variations (CNV) in PLN by real-time PCR
(RT-PCR) using 7500 Real-Time PCR Systems (Applied
Biosystems). Reactions were run in duplicates in 15 μl
reaction volume including MESA GREEN MasterMix
Plus, Low ROX (Eurogentec, Belgium), with final primer
concentrations in reaction: forward 133 nM, reverse 400
nM and 20 ng of DNA. Albumin (ALB) was used as a
reference gene. In each assay control DNA and no-
template control were included. The PCR conditions
were: 10 min at 95°C, followed by 40 cycles of denatur-
ation at 95°C for 15 sec and annealing and elongation
step at 60°C for 1 min. Each amplification stage was
followed by dissociation stage: 95°C for 15 sec, 60°C for
1 min. Data were analyzed using the 7500 analysis soft-
ware (version 1.2.3) and calculated using ΔΔCt method.
Results
We indentified three heterozygous variants in exon 2 of
PLN [NM_002667.3]: a novel c.9_10insA:(p.Val4Serfs*15)
and two previously described: c.25C > T:(p.Arg9Cys)
(rs111033559) and c.26G > T:(p.Arg9Leu). Arg9Leu was
found by WES and the other two variants by Sanger
sequencing. All variants were confirmed by Sangersequencing of two DNA samples from the same individ-
ual, including a sample isolated from independently col-
lected blood. Neither these nor any other protein coding
PLN variants were found in age and sex matched control
group of 200 individuals.
PLN c.9_10insA:(p.Val4Serfs*15)
The novel PLN:c.9_10insA:(p.Val4Serfs*15) variant was
identified in a 31-year-old male patient treated with radio-
frequency ablation for Wolf-Parkinson-White (WPW)
syndrome. He was initially diagnosed with a suspicion of
LVNC but mild hypertrabeculation in the LV apex did not
meet the criteria for LVNC. His left ventricular size and
function were normal (LVEF = 62%). Ulcerative colitis was
a coexistent disease. His both parents were asymptomatic,
and normal in 12-lead standard electrocardiogram and
two-dimensional Doppler echocardiogram. His 51-year-
old mother, also the variant carrier, was found to have
high normal left ventricular ejection fraction of 76%
and concentric left ventricular remodelling, left ven-
tricular mass was normal (72 g/m2). Chromatogram il-
lustrating PLN c.9_10insA:(p.Val4Serfs*15) variant is
shown in Figure 1A.
PLN c.25C > T:(p.Arg9Cys)
The c.25C > T:(p.Arg9Cys) mutation was identified in a
30-year-old female who had had acute onset of DCM
following viral-like syndrome at the age of 21 years with
subsequent exacerbations of heart failure not responding
to standard treatment and leading to heart transplant at
the age of 22 years. There was no DCM or sudden car-
diac deaths in the family. Her parents and two siblings
are asymptomatic and refused genetic testing. Chro-
matogram illustrating Arg9Cys mutation is shown in
Figure 1B.
PLN c.26G > T:(p.Arg9Leu)
In WES mean coverage of DNA sample with the
Arg9Leu mutation was 62-fold with 83.54% of the tar-
geted exons covered at least 10× and 78.8% covered at
least 20×. The total number of variants in the proband
was 64754, of which 3813 were considered rare (fre-
quency in the database from NHLBI GO exome sequen-
cing project (ESP) [12] less-than or equal to 0.001 and
frequency in our in-house database of 200 exomes less
or equal to 0.01. Further filtering for variants in genes
linked with DCM from Human Gene Mutation Database
(HGMD) [13] revealed 48 variants, of which two were lo-
cated in exons: PLN: c.26G > T:(p.Arg9Leu) in phosho-
lamban and DES:c.665G > A:(p.Arg222His) (rs367961979)
in desmin. Both variants were found in the proband III-1
and his daughter IV-2 with DCM and absent in two
healthy family members III-4 and IV-3 (Figure 2). The
proband at the time of genetic inquest was 55 years old,
Figure 1 Chromatograms of PLN c.9_10insA:(p.Val4Serfs*15) and c.25C > T:p.Arg9Cys variants. Chromatograms from direct sequencing by
the Sanger method showing the c.9_10insA:(p.Val4Serfs*15) (A) and c.25C > T:p.Arg9Cys (B) variants. Below chromatogram A predicted effect of
c.9_10insA:(p.Val4Serfs*15) variant on PLN protein sequence. Black font color denotes unaffected amino acid residues, green font original PLN amino
acid sequence, red font altered amino acid residues of PLN in c.9_10insA:(p.Val4Serfs*15) variant.
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disease pulmonary edema in the course of atrial flutter
(165/min) was present with dilated left ventricle 6.7 cm,
decreased LVEF 30% and moderate mitral insufficiency on
echocardiography. On intravenous amiodarone the patient
returned to sinus rhythm. Additionally, on 12-lead ECG
low voltage QRS complexes were found in the limb leads
with QRS width of 104 ms (Figure 3A). Coronary angiog-
raphy was normal. During a 4-year follow-up progression
of heart failure symptoms, paroxysmal atrial fibrillation
and ventricular arrhythmia 1900Vex/24 h with 5 episodes
of nonsustained ventricular tachycardia (nsVT) (4 beats)
occurred despite standard heart failure treatment plus
amiodarone. Severe mitral valve regurgitation (vena con-
tracta of 8 mm) due to restriction of the mitral valve leaf-
lets was present (Figure 4). The patient refused to undergo
either mitral valve insufficiency correction or implantable
cardioverter-defibrilator (ICD) therapy. NT-proBNP and
troponin I serum concentrations were constantly elevated
(914.30 pg/mL and 0.136 ng/mL, respectively). The only
comorbidity was hyperlipidemia. The first manifestations
of the disease in the proband’s daughter were fatigue and
frequent palpitations at 30 years of age. There were no ab-
normalities on physical examination at admission and no
cardiovascular risk factors. Low voltage QRS complexes in
all leads and ST-T changes in leads V4-V6 were found
(Figure 3B). All laboratory tests were normal with the ex-
ception of NT-proBNP, whose concentration was mildly
elevated (586 pg/mL). On 24 h-Holter ECG monitoring
frequent ventricular ectopy 3430/24 h with 3 episodes ofnsVT (3–6 beats) was observed. Echocardiogram revealed
dilated left ventricle 60 mm, %LVE 128.3 global hypokin-
esis of the left ventricle with LVEF of 35%, slight mitral in-
sufficiency, normal RV function and non-dilated atria.
CMR showed increased left ventricular volume and
marked hypokinesis of the left ventricle [LVEF of 33%,
LVEDV/BSA 135 ml/m2 (N: 62–96), normal LV mass 60
g/m2 (N:47–77) (Figure 5)]. Contrast enhanced CMR im-
aging showed diffuse areas of midwall late gadolinium en-
hancement in the anterior wall and interventricular
septum, which are typical of non-ischemic origin and may
be observed in various diseases such as DCM, myocarditis
or HCM [14]. The patient received standard heart failure
treatment. During a two-year follow-up while on metopro-
lol tartate 100 mg and ramipril 7.5 mg, the number of ven-
tricular arrhythmia episodes increased 10191 Vex/24 h,
34nsVT, 540 couplets while in sinus rhythm 45–116, mean
73 bpm. The patient had clinical indications to ICD im-
plantation, however she did not agree. The proband’s
mother and the mother’s sister died suddenly at age 46
and 40, respectively.
In 19/161 patients the PLN:c.-36 A > C (rs77186188)
promoter variant was found (heterozygous in 18 patients
and one homozygous, allelic frequency 6.21%). In another
DCM patient heterozygous 5′UTR variant PLN:c.-56C >
T (rs189611501) was found.
Discussion
While screening 161 Polish patients referred for clinical
cardiomyopathy diagnosis for PLN single nucleotide
Figure 2 PLN c.26G > T :p.Arg9Leu and DES:c.665G > A:(p.Arg222His) variants IGV view of PLN c.26G > T :p.Arg9Leu variant found by
whole exome seguencing (A), pedigree of the family (B) and chromatograms from direct sequencing by the Sanger method showing
the PLN p.Arg9Leu variant (C) and DES Arg222His variant (D) in the proband. Pedigree: squares represent males and circles represent
females. An arrowhead denotes the proband. A diagonal line marks deceased individuals. Solid black symbols denote dilated cardiomyopathy
and grey shading sudden death. Open symbols with asterisk denote unaffected individuals. The presence or absence of a mutation is indicated
by a +/− symbol, respectively (top PLN Arg9Leu variant, bottom DES Arg222His variant).
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ants of note: a novel c.9_10insA:(p.Val4Serfs*15) and two
previously described variants - c.25C > T:(p.Arg9Cys) and
c.26G > T:(p.Arg9Leu). In the controls there were no vari-
ants in the PLN coding sequence.
The novel c.9_10insA:(p.Val4Serfs*15) variant was
found in a patient with WPW syndrome with suspectedbut eventually not confirmed diagnosis of LVNC and his
mother with normal LVEF and concentric left ventricu-
lar remodeling. The c.9_10insA is predicted to encode a
17 amino acid protein with only 3 initial residues corre-
sponding to PLN sequence (Figure 1A). Thus, the
c.9_10insA mutation can be regarded as a null mutation
similar to complete deletion, which so far has not been
Figure 3 Standard 12-lead electrocardiogram in the proband (A) and his daughter (B). Regular sinus rhythm in both subjects, low QRS
voltage in limb leads (A), and in all leads (B). In addition, in the proband (A) ST-T changes in inferolateral leads as well as left atrial enlargement.
Diffuse ST-T changes were identified in the probands’s daughter (B).
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to a truncated PLN protein is c.116A > C:p.Leu39Ter
(rs111033560) [8]. Although no clear function of PLN
Leu39Ter could be demonstrated, the truncated protein
was detected in transfected human embryonic kidney
(HEK) 293 cells raising a possibility that it may be
expressed and exert pathologic effects and thus should
not be regarded as a bona fide null. Whereas pathogenicityFigure 4 Two-dimensional echocardiographic study of proband III-1.
mitral valve regurgitation (vena contracta of 8 mm) due to restriction of the m
Enlarged left ventricle, left ventricular end-diastolic volume (LVEDV 154 ml) wiof p.Leu39Ter homozygosity is supported by two siblings
who both had DCM and HTx [8], the effect of a single
dose of p.Leu39Ter is less clear. Once the probands were
excluded, there were a total of 16 described family mem-
bers with Leu39Ter mutation from whom only two were
clearly affected (DCM and HCM, respectively), four had
left ventricular hypertrophy and ten were asymptomatic
[7,8]. However, the subject with HCM was a 3-year-oldA: Parasternal long axis view in systole with color flow Doppler. Severe
itral valve leaflets. B: Apical four-chamber view, speckle tracking method.
th low ejection fraction (LVEF 37%). Enlarged left atrium chamber.
Figure 5 Cardiac magnetic resonance cine image of proband’s daughter IV-2, 4-chamber image (A) demonstrating dilated left ventricle
in end-diastole, late gadolinium enhancement images in 2-chamber view (B) and mid-ventricular short axis view (C) showing mid wall
enhancement of the anterior and inferior wall (B) and interventricular septum (C).
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38-year-old mother raising a possibility that the PLN de-
fect was not casually linked with HCM in this family [7].
Single dose of Leu39Ter has also been found in a 57-year-
old female with a normal ECG, thickened aortic valves,
moderate aortic regurgitation but normal LVEF (60%)
from ClinVar project [15]. Thus, our results and the data
reported in the literature indicate that in humans hetero-
zygous null PLN mutations may have low penetrance or
maybe are not pathogenic. This is a clinically important
issue as it emphasizes that in dominant disorders null
gene variants should not be presumed to be pathogenic
without additional evidence.
PLN Arg9Cys mutation found by us in a 30-year-old
heart transplantation recipient has been previously de-
scribed in a large family with DCM with a similarly ag-
gressive disease course as in our patient [16]. No history
of DCM in our patient’s family suggests a de novo muta-
tion, however we could not confirm this since her relatives
refused genetic testing. In our study the Arg9Leu muta-
tion was found in a familial DCM case in 55-year-old pro-
band and his 30-year-old daughter. In addition they both
carried the c.665G > A:(p.Arg222His) (rs367961979) vari-
ant in DES which was absent in two other healthy family
members. Allele frequency of this variant is 0.0233% (two
heterozygotes among 4300 participants of ESP project)
[12]. rs367961979 affects conserved amino acid and is lo-
calized in helical 1B domain of desmin protein. SIFT and
PolyPhen2 prediction scores indicate that it is damaging
and possibly damaging, respectively. Although it is intri-
guing that ~50 % of patients with mutation in DES have
cardiomyopathy, most commonly DCM [17], at present
we classify DES c.665G > A (p.Arg222His) as a variant of
unknown significance (VUS).
Similarly to what was seen in two unrelated female
Arg9Leu mutation carriers studied by Medeiros et al. [5]substantial clinical differences were observed between the
two Arg9Leu mutation carriers from the family studied by
us. The proband’s daughter had the onset of the disease 2
decades earlier than her father, no atrial arrhythmia, low
QRS voltage in all leads (proband in limb leads only) and
no mitral insufficiency. It is possible that clinical manifes-
tations of the disease are linked to genetic background or
sex. In humans basal PLN Ser16 phosphorylation in males
is higher than in females [18], thus it is possible that muta-
tions influencing Ser16 phosphorylation have higher im-
pact on females.
The 9th amino acid of PLN is an apparent hot spot for
mutation as the arginine at this position has also been
reported to mutate to His in addition to Cys or Leu
[5,16]. Functional studies indicate that possible mechan-
ism of detrimental effect of the Arg9Leu and Arg9Cys
mutations on PLN protein function is associated with
impaired phosphorylation by PKA and impaired SERCA
activity [16,19,20]. Mice overexpressing Arg9Cys trans-
gene under the control of cardiac α-myosin heavy chain
promoter had developed DCM and heart failure pheno-
type [16]. Recently a detailed mechanism of deleterious
effect of Arg9Cys mutation on SERCA function was pro-
posed [21]. Arg9Cys mutation stabilizes PLN pentamers
by disulphide bridges formation and thus prevents phos-
phorylation of PLN by PKA and formation of PLN mono-
mers. Disulfide bonds are more stable under oxidative
stress conditions which are frequent in such a pathological
states as heart failure [22]. Furthermore, under oxidative
conditions the Arg9Cys mutant PLN can form dimers also
with WT PLN, which were proposed to be defective in
regulating SERCA activity [21].
Based on a report on a large 624 kb duplication in-
cluding the PLN gene in a childhood-onset DCM [23]
case we screened for PLN gene CNV but did not detect
any. PLN promoter variant −36 A > C (rs77186188) was
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project (6.21% vs. 7%, respectively). Initially −36 A > C
variant was reported as associated with heart failure, how-
ever further studies on larger groups of subjects did not
confirm this finding [24,25]. In one DCM patient a rare 5′
UTR variant (PLN:c.-56C > T, rs189611501) was found.
This variant has an allelic frequency of 0.0014 (3 carriers
per 1092 subjects) and probably is a rare polymorphism.
Conclusions
In conclusion, our study supports the pathogenicity of
PLN Arg9Cys and Arg9Leu variants, thus emphasizing the
importance of phospholamban amino acid position 9. The
phenotype of two c.9_10insA:(p.Val4Serfs*15) variant
carriers suggests that heterozygous truncating PLN mu-
tations have low penetrance or do not cause cardiomy-
opathy at all.
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